Career history of Shirley M. Clift
Former positions of Shirley M. Clift
| Companies | Position | Start | End |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INC. | General Counsel | 2009-12-31 | 2018-12-31 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | General Counsel | 2008-12-31 | 2008-12-31 |
Training of Shirley M. Clift
| University of California, Berkeley | Undergraduate Degree |
Statistics
International
| United States | 4 |
Operational
| General Counsel | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Stock Market
- Insiders
- Shirley M. Clift
- Experience
